The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A10 | Drugs used in diabetes | |
| 3 | A10X | Other drugs used in diabetes | |
| 4 | A10XX | Other drugs used in diabetes |
| Code | Title | |
|---|---|---|
| A10XX01 |
| Active Ingredient | Description | |
|---|---|---|
| Teplizumab |
Teplizumab-mzwv binds to CD3 (a cell surface antigen present on T lymphocytes) and delays the onset of Stage 3 type 1 diabetes in adults and pediatric patients aged 8 years and older with Stage 2 type 1 diabetes. The mechanism may involve partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes. Teplizumab-mzwv leads to an increase in the proportion of regulatory T cells and of exhausted CD8+ T cells in peripheral blood. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| TZIELD Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
